Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in IgA Nephropathy
Travere Therapeutics announced that the USPTO issued a Notice of Allowance for a patent application covering methods of using FILSPARI in IgA Nephropathy. The allowed patent is expected to provide U.S. coverage for these uses through October 2037, strengthening the intellectual property moat for the drug's primary indication.
Key figures
- Drug Name
- FILSPARI (sparsentan)
- Patent expiry
- October 2037
- Patent application number
- 19/253,088
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.